These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2693621)

  • 1. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
    Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
    J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
    Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
    Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
    Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
    Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
    Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
    Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
    Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
    Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
    Roila F; Tonato M; Basurto C; Minotti V; Ballatori E; del Favero A
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylprednisolone for the control of CMF-induced emesis.
    Chiara S; Campora E; Lionetto R; Bruzzi P; Rosso R
    Am J Clin Oncol; 1987 Jun; 10(3):264-7. PubMed ID: 3296735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
    Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
    Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
    Gez E; Goodman S; Isacson R; Gerra C; Sulkes A
    Oncology; 1986; 43(3):173-5. PubMed ID: 3754627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An audit of antiemetic use with CMF chemotherapy.
    Brown RS; Brown TK; Hoare D; Gaze MN
    Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiemetic treatments associated with antineoplastic chemotherapy].
    Tres Sánchez A; Sáez Martínez MJ; Mayordomo Cámara JJ; Guillén Lloveria G; Sáenz Cusi A
    An Med Interna; 1990 May; 7(5):229-32. PubMed ID: 2102716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
    Tsavaris NB; Koufos C; Katsikas M; Dimitrakopoulos A; Athanasiou E; Linardaki G
    J Pain Symptom Manage; 1999 Sep; 18(3):218-22. PubMed ID: 10517044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
    Roila F; Minotti V; Ballatori E; Basurto C; Tonato M
    Tumori; 1985 Oct; 71(5):455-8. PubMed ID: 3840612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
    Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.